PortalPublikationenPatient-Relevant Costs for Organ Preservation versus Radical...

Patient-Relevant Costs for Organ Preservation versus Radical Resection in Locally Advanced Rectal Cancer

Standard

Patient-Relevant Costs for Organ Preservation versus Radical Resection in Locally Advanced Rectal Cancer. / Wurschi, Georg W; Rühle, Alexander; Domschikowski, Justus; Trommer, Maike; Ferdinandus, Simone; Becker, Jan-Niklas; Boeke, Simon; Sonnhoff, Mathias; Fink, Christoph A; Käsmann, Lukas; Schneider, Melanie; Bockelmann, Elodie; Krug, David; Nicolay, Nils H; Fabian, Alexander; Pietschmann, Klaus.

in: CANCERS, Jahrgang 16, Nr. 7, 1281, 26.03.2024.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wurschi, GW, Rühle, A, Domschikowski, J, Trommer, M, Ferdinandus, S, Becker, J-N, Boeke, S, Sonnhoff, M, Fink, CA, Käsmann, L, Schneider, M, Bockelmann, E, Krug, D, Nicolay, NH, Fabian, A & Pietschmann, K 2024, 'Patient-Relevant Costs for Organ Preservation versus Radical Resection in Locally Advanced Rectal Cancer', CANCERS, Jg. 16, Nr. 7, 1281. https://doi.org/10.3390/cancers16071281

APA

Wurschi, G. W., Rühle, A., Domschikowski, J., Trommer, M., Ferdinandus, S., Becker, J-N., Boeke, S., Sonnhoff, M., Fink, C. A., Käsmann, L., Schneider, M., Bockelmann, E., Krug, D., Nicolay, N. H., Fabian, A., & Pietschmann, K. (2024). Patient-Relevant Costs for Organ Preservation versus Radical Resection in Locally Advanced Rectal Cancer. CANCERS, 16(7), [1281]. https://doi.org/10.3390/cancers16071281

Vancouver

Wurschi GW, Rühle A, Domschikowski J, Trommer M, Ferdinandus S, Becker J-N et al. Patient-Relevant Costs for Organ Preservation versus Radical Resection in Locally Advanced Rectal Cancer. CANCERS. 2024 Mär 26;16(7). 1281. https://doi.org/10.3390/cancers16071281

Bibtex

@article{fff2e6a0ca104889af62595abe060d6a,
title = "Patient-Relevant Costs for Organ Preservation versus Radical Resection in Locally Advanced Rectal Cancer",
abstract = "Total neoadjuvant therapy (TNT) is an evolving treatment schedule for locally advanced rectal cancer (LARC), allowing for organ preservation in a relevant number of patients in the case of complete response. Patients who undergo this so-called {"}watch and wait{"} approach are likely to benefit regarding their quality of life (QoL), especially if definitive ostomy could be avoided. In this work, we performed the first cost-effectiveness analysis from the patient perspective to compare costs for TNT with radical resection after neoadjuvant chemoradiation (CRT) in the German health care system. Individual costs for patients insured with a statutory health insurance were calculated with a Markov microsimulation. A subgroup analysis from the prospective {"}FinTox{"} trial was used to calibrate the model's parameters. We found that TNT was less expensive (-1540 EUR) and simultaneously resulted in a better QoL (+0.64 QALYs) during treatment and 5-year follow-up. The average cost for patients under TNT was 4711 EUR per year, which was equivalent to 3.2% of the net household income. CRT followed by resection resulted in higher overall costs for ostomy care, medication and greater loss of earnings. Overall, TNT appeared to be more efficacious and cost-effective from a patient's point of view in the German health care system.",
author = "Wurschi, {Georg W} and Alexander R{\"u}hle and Justus Domschikowski and Maike Trommer and Simone Ferdinandus and Jan-Niklas Becker and Simon Boeke and Mathias Sonnhoff and Fink, {Christoph A} and Lukas K{\"a}smann and Melanie Schneider and Elodie Bockelmann and David Krug and Nicolay, {Nils H} and Alexander Fabian and Klaus Pietschmann",
year = "2024",
month = mar,
day = "26",
doi = "10.3390/cancers16071281",
language = "English",
volume = "16",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "7",

}

RIS

TY - JOUR

T1 - Patient-Relevant Costs for Organ Preservation versus Radical Resection in Locally Advanced Rectal Cancer

AU - Wurschi, Georg W

AU - Rühle, Alexander

AU - Domschikowski, Justus

AU - Trommer, Maike

AU - Ferdinandus, Simone

AU - Becker, Jan-Niklas

AU - Boeke, Simon

AU - Sonnhoff, Mathias

AU - Fink, Christoph A

AU - Käsmann, Lukas

AU - Schneider, Melanie

AU - Bockelmann, Elodie

AU - Krug, David

AU - Nicolay, Nils H

AU - Fabian, Alexander

AU - Pietschmann, Klaus

PY - 2024/3/26

Y1 - 2024/3/26

N2 - Total neoadjuvant therapy (TNT) is an evolving treatment schedule for locally advanced rectal cancer (LARC), allowing for organ preservation in a relevant number of patients in the case of complete response. Patients who undergo this so-called "watch and wait" approach are likely to benefit regarding their quality of life (QoL), especially if definitive ostomy could be avoided. In this work, we performed the first cost-effectiveness analysis from the patient perspective to compare costs for TNT with radical resection after neoadjuvant chemoradiation (CRT) in the German health care system. Individual costs for patients insured with a statutory health insurance were calculated with a Markov microsimulation. A subgroup analysis from the prospective "FinTox" trial was used to calibrate the model's parameters. We found that TNT was less expensive (-1540 EUR) and simultaneously resulted in a better QoL (+0.64 QALYs) during treatment and 5-year follow-up. The average cost for patients under TNT was 4711 EUR per year, which was equivalent to 3.2% of the net household income. CRT followed by resection resulted in higher overall costs for ostomy care, medication and greater loss of earnings. Overall, TNT appeared to be more efficacious and cost-effective from a patient's point of view in the German health care system.

AB - Total neoadjuvant therapy (TNT) is an evolving treatment schedule for locally advanced rectal cancer (LARC), allowing for organ preservation in a relevant number of patients in the case of complete response. Patients who undergo this so-called "watch and wait" approach are likely to benefit regarding their quality of life (QoL), especially if definitive ostomy could be avoided. In this work, we performed the first cost-effectiveness analysis from the patient perspective to compare costs for TNT with radical resection after neoadjuvant chemoradiation (CRT) in the German health care system. Individual costs for patients insured with a statutory health insurance were calculated with a Markov microsimulation. A subgroup analysis from the prospective "FinTox" trial was used to calibrate the model's parameters. We found that TNT was less expensive (-1540 EUR) and simultaneously resulted in a better QoL (+0.64 QALYs) during treatment and 5-year follow-up. The average cost for patients under TNT was 4711 EUR per year, which was equivalent to 3.2% of the net household income. CRT followed by resection resulted in higher overall costs for ostomy care, medication and greater loss of earnings. Overall, TNT appeared to be more efficacious and cost-effective from a patient's point of view in the German health care system.

U2 - 10.3390/cancers16071281

DO - 10.3390/cancers16071281

M3 - SCORING: Journal article

C2 - 38610958

VL - 16

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 7

M1 - 1281

ER -